Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TB001 in Healthy Subjects
NCT05308940Phase 1Completed
- Sponsor
- Shenzhen Turier Biotech
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tb001 in Liver Fibrosis (LF) (4 arms), sponsored by Shenzhen Turier Biotech. Primary endpoint: Incidence and severity of adverse events (AEs). Started Jan 2022; status: completed.
02
Drugs
tb001
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT05308940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308940.